InvestorsHub Logo
Followers 30
Posts 2196
Boards Moderated 1
Alias Born 03/21/2014

Re: None

Tuesday, 05/09/2023 11:53:53 AM

Tuesday, May 09, 2023 11:53:53 AM

Post# of 407
That's a pretty nice 10Q and a terribly sweet 8k today.

https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=317472177&type=HTML&symbol=BLUE&cdn=49eb2e78599a3f8993e1dbd77103d6c4&companyName=bluebird+bio+Inc.&formType=10-Q&formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&dateFiled=2023-05-09


https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=317472175&type=PDF&symbol=BLUE&cdn=a27bb9bb8a132409a5d38d92346a9d24&companyName=bluebird+bio+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2023-05-09

["The first quarter of 2023 saw us continue to establish and scale the commercial model for ex-vivo gene therapy in the US through the
launches of ZYNTEGLO and SKYSONA and lay the foundation for revenue generation for years to come for bluebird," said Andrew
Obenshain, chief executive officer, bluebird bio. "Additionally, with the submission of the lovo-cel BLA for sickle cell disease in April,
bluebird has taken a pivotal step towards realizing its most significant opportunity yet -- bringing a transformative gene therapy to
individuals living with sickle cell disease."]
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BLUE News